Transcranial Magnetic Stimulation (Repetitive Transcranial Magnetic Stimulation, rTMS)

Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive treatment that delivers repetitive pulses of an MRI-strength magnetic field from a coil placed over the scalp. Powered by a rapidly pulsed current, the magnetic field passes unimpeded through the skull and stimulates brain tissue beneath, inducing currents that may help normalize activity in the area stimulated without producing seizure activity.

The FDA approved rTMS in 2008 as a treatment to alleviate symptoms of mildly treatment-resistant depression, in which patients have not found relief from antidepressant medication. It has also been studied as a possible treatment for a number of other disorders, such as schizophrenia, pain, stroke, and amyotrophic lateral sclerosis (ALS).

TMS was introduced in 1985, based on technology for experimentally probing brain activity. TMS was initially hoped to offer similar benefits to electroconvulsive therapy (ECT), without its drawbacks, such as impacting memory. ECT is still offered to patients who do not benefit from antidepressant medication, and is carried out under general anesthesia to limit discomfort from the convulsions it induces.

By contrast, rTMS is carried out while the patient is awake and reclining in a specially equipped chair. Sessions usually last 20-40 minutes, five days a week, typically for six weeks.

In open-label clinical trials, after 4-6 weeks of treatment, one out of two patients treated with rTMS for depression experienced a reduction in symptoms of 50% or more, and one out of three experienced remission. The effect was lower in patients who had exhibited resistance to more antidepressants.

The persistence of the effect is still being investigated. The therapeutic effect has been reported to last for at least six months, with intermittent repeat sessions as an option to prevent relapse. (1) After coming in for daily treatments during the initial treatment phase, patients should continue to be monitored and receive maintenance therapy if needed, which may include receiving a medication.

For patients with treatment-resistant depression, rTMS has been approved in Canada, Australia, New Zealand, the European Union, and Israel in addition to in the United States.

The therapy is conducted with earplugs to reduce the noise of the magnet, which makes a rapid “woodpecker”-like tapping. About one-third of patients experience a mild headache following treatment. Another third of patients notice a prickly, tingly sensation on their scalp while the stimulating pulses are being administered. One in 1,000 patients experience a provoked seizure; while this risk is similar to that from some antidepressant medications (e.g. bupropion) seizures related to rTMS exposure have terminated soon after the magnetic stimulation ends.

While clinical trials indicate TMS is generally safe and well-tolerated, the effectiveness overall is considered modest (effect size about 0.5 [2]), so in evidence-based practice guidelines it is not classified as a first-line treatment although it may be offered prior to more stringent measures such as ECT.

Due to its non-invasive nature and minimal risk of lasting side effects, rTMS has been studied as a possible treatment for a wide range of psychiatric conditions. The data are strongest for use in treatment of unipolar major depressive disorder. In schizophrenia, it has been under investigation to reduce the likelihood of hearing nonexistent voices (auditory hallucination) and of negative disease symptoms, such as apathy. It has also been studied for relieving symptoms of Parkinson’s disease, dystonia, tinnitus, anxiety, migraine, eating disorders and bipolar disorders, as well as for pain, stroke and ALS, among other conditions.


1. Janicak PG, Nahas Z, Lisanby SH, Solvason HB, Sampson SM, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimul. 2010;3:187–199.

2. O’Reardon, JP, Solvason, HB, Janicak, PG, Sampson, S, Isenberg, KE, Nahas, Z, McDonald, WM, Avery, D, Fitzgerald, PB, Loo, C, Demitrack, MA, George, MS, Sackeim, HA. Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multi-Site Randomized Controlled Trial. Biol Psychiatry. 2007; 62:1208-1216.

Reviewed August 17, 2012
Ian Cook, MD
Member, International Neuromodulation Society
Associate Director of the Laboratory of Brain, Behavior, and Pharmacology, University of California, Los Angeles (UCLA); Professor in the Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine at UCLA; Research Scientist at the UCLA Brain Research Institute and Semel Institute for Neuroscience and Human Behavior; and Director of the UCLA Depression Research and Clinic Program

Last Updated on Sunday, November 21, 2021 08:17 PM